FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:441-442 February 10, 2000 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Ritz, E.

To the Editor: In their review of nephropathy in pa-tients with type 2 diabetes mellitus (Oct. 7 issue),¹ Ritz and Orth focus on treatment with antihypertensive drugs, mainly angiotensin-converting–enzyme inhibitors. However, other treatments can be effective, suggesting that there may be additional pathogenic mechanisms in diabetic nephropathy.

Cytokines, including tumor necrosis factor (TNF-), have been implicated in the development and progres-sion of diabetic nephropathy.² Pentoxifylline is a methylxanthine derivative with rheologic properties that is also a modulator of immune function, since it can decrease the serum TNF- level. Pentoxifylline reduces proteinuria in patients with either insulin-dependent diabetes or non-insulin-dependent . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.